期刊
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
卷 10, 期 10, 页码 1165-1176出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERI.12.110
关键词
carbapenemases; CTX-M-beta-lactamases; ExPEC; extraintestinal pathogenic Escherichia coli; KPC; laboratory detection; NDM; OXA-48; plasmid-mediated AmpC beta-lactamases; treatment options
资金
- Merck
- Astra Zeneca
Expert Rev. Anti Infect Ther. 10(10), 1165-1176 (2012) Escherichia coli remains one of the most frequent causes of nosocomial and community-acquired bacterial infections including urinary tract infections, enteric infections and systemic infections in humans. Extraintestinal pathogenic E. coli (ExPEC) had emerged during the 2000s as an important player in the resistance to antibiotics, especially to the cephalosporins and fluoroquinolones. Most importantly, among ExPEC is the increasing recognition of isolates producing 'newer beta-lactamases' that consist of plasmid-mediated AmpC beta-lactamases (e.g., CMY), extended-spectrum beta-lactannases (e.g., CTX-M) and carbapenemases (e.g., New Delhi metallo-beta-lactamase, Klebsiella pneumonaie carbapenemase and OXA-48). This review will highlight recent aspects on antimicrobial resistance in ExPEC, including the laboratory detection of these isolates, and describe some treatment options for infections due to antimicrobial-resistant isolates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据